Results 101 to 110 of about 14,967 (152)

Bioavailability Enhancement and Polymorphic Stabilization of One BCS Class IV Metastable Drug Through Novel Formulation Approach. [PDF]

Turk J Pharm Sci
Panda R, Lankalapalli S.
europepmc   +1 more source

Intramural Esophageal Hematoma as a Complication of Percutaneous Coronary Intervention: A Case Report. [PDF]

Am J Case Rep
Xu L, Jiang J, Yin Y, Chen Y.
europepmc   +1 more source

CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026. [PDF]

Cardiovasc Interv Ther
Ozaki Y, Tobe A, Onuma Y, Miyashita K, Kobayashi Y, Amano T, Yamaji K, Ishii H, Muramatsu T, Ismail TF, Kohsaka S, Nakagawa Y, Morino Y, Uemura S, Tsujita K, Shinke T, Ako J, Yajima J, Maekawa Y, Shite J, Igarashi Y, Shiode N, Okamura A, Ogawa T, Yamaguchi J, Tamura T, Tsuji T, Hayashida K, Sugano T, Okura H, Okayama H, Kawaguchi K, Zen K, Takahashi S, Nakazato K, Suematsu N, Hironaga K, Matoba T, Iida O, Ishihara M, Ohta M, Harada M, Ozaki R, Izawa H, Murohara T, Ueno T, Nakamura M, Ikari Y, Serruys PW, Kozuma K, Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT).   +50 more
europepmc   +1 more source

Study protocol for low-dose evaluation of aspirin in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention (LEAST): a multicenter, double-blind, randomized controlled clinical trial. [PDF]

Ann Med
Zheng W, Gong ZT, Qian HY.
europepmc   +1 more source

Evaluation of the Anti-inflammatory Effects of Ticagrelor and Prasugrel as Add-On Therapy to Aspirin in Diabetic Patients Post-percutaneous Coronary Intervention. [PDF]

Cureus
Panigrahy A, Mekala P, Pingali U, Vs B.
europepmc   +1 more source

Analysis of Treatment Pattern of Antiplatelet in First-Ever Ischemic Stroke Without Previous Antiplatelet Use: A Real-World Distributed Network Analysis of 11 Observational Korean Databases Using a Common Data Model. [PDF]

J Korean Med Sci
Park SH, Lee KJ, Kim J, Seo SI, Lee DY, Park RW, Rhee SY, Cha JM, Yang HJ, Jang JW, Jung S, Lee J, Lee M, Lee SH, Kim C, Bae JS, Kim YJ, Lee JH, Kim Y.   +18 more
europepmc   +1 more source

Ticagrelor-Induced Complete Heart Block. [PDF]

Cureus
Farooq Z, Singh SK, Rao S, Ansari A, Kumar D.   +4 more
europepmc   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). [PDF]

Br J Clin Pharmacol
Dello Russo C, Frater I, Kuruvilla R, Lip S, O'Neill H, Burke K, Chaplin V, Doney ASF, Elyas S, Greaves N, Harding S, Hargroves D, Hayward J, Hughes DA, Hughes TAT, Kondapally S, Mok P, Peace A, Rafi I, Ray S, Stinton V, Venetucci L, Pirmohamed M.   +22 more
europepmc   +1 more source

Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/Smad2 pathway. [PDF]

Biomed Pharmacother
Kang Y, Amoafo EB, Entsie P, Layek B, Grandgenett PM, Hollingsworth MA, di Magliano MP, Liverani E.   +7 more
europepmc   +1 more source

Antiplatelet Therapy Tailored by Ethnicity: Further Insights From a Multiethnic Southeast Asian Cohort. [PDF]

JACC Asia
Ahn JH, Kim MC.
europepmc   +1 more source